Article

Challenges in Treating TRK Fusion Cancer

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

Transcript

TRK [tropomyosin receptor kinase] fusion cancer is quite rare in the common cancers. We don’t know the exact incidence, but we believe it is below 1%. So it is very difficult to find in the common cancers and we need some strategies of how to identify the patients. But then it’s very frequent in some very rare cancer, so this also complicates it. But we know, for instance, in infantile fibrosarcoma and secondary breast cancer it’s almost pathognomonic so It’s needed to state the diagnosis.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com